- Home
- RNA vs IMVT Comparison
RNA vs IMVT Comparison
Compare RNA & IMVT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RNA
- IMVT
- Stock Information
- Founded
- RNA 2012
- IMVT N/A
- Country
- RNA United States
- IMVT United States
- Employees
- RNA N/A
- IMVT N/A
- Industry
- RNA Biotechnology: Pharmaceutical Preparations
- IMVT Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- RNA Health Care
- IMVT Health Care
- Exchange
- RNA Nasdaq
- IMVT Nasdaq
- Market Cap
- RNA 4.4B
- IMVT 4.2B
- IPO Year
- RNA 2020
- IMVT N/A
- Fundamental
- Price
- RNA $33.35
- IMVT $27.31
- Analyst Decision
- RNA Strong Buy
- IMVT Strong Buy
- Analyst Count
- RNA 10
- IMVT 11
- Target Price
- RNA $63.60
- IMVT $48.10
- AVG Volume (30 Days)
- RNA 1.1M
- IMVT 799.9K
- Earning Date
- RNA 11-07-2024
- IMVT 02-10-2025
- Dividend Yield
- RNA N/A
- IMVT N/A
- EPS Growth
- RNA N/A
- IMVT N/A
- EPS
- RNA N/A
- IMVT N/A
- Revenue
- RNA $10,117,000.00
- IMVT N/A
- Revenue This Year
- RNA N/A
- IMVT N/A
- Revenue Next Year
- RNA N/A
- IMVT N/A
- P/E Ratio
- RNA N/A
- IMVT N/A
- Revenue Growth
- RNA N/A
- IMVT N/A
- 52 Week Low
- RNA $8.37
- IMVT $24.61
- 52 Week High
- RNA $56.00
- IMVT $45.58
- Technical
- Relative Strength Index (RSI)
- RNA 30.43
- IMVT 44.77
- Support Level
- RNA $32.04
- IMVT $26.19
- Resistance Level
- RNA $34.35
- IMVT $28.08
- Average True Range (ATR)
- RNA 2.07
- IMVT 1.01
- MACD
- RNA -0.55
- IMVT -0.03
- Stochastic Oscillator
- RNA 6.24
- IMVT 32.73
About RNA Avidity Biosciences Inc.
Avidity Biosciences Inc is a biotechnology company. The company develops novel Antibody Oligonucleotide Conjugates therapies designed to overcome the current limitations of oligonucleotide therapies in order to treat a wide range of serious diseases. Its product, AOC 1001, is designed to treat a rare monogenic muscle disease.
About IMVT Immunovant Inc.
Immunovant Inc is a clinical-stage biopharmaceutical company. It is focused on enabling normal lives for patients with autoimmune diseases. The company's product includes batoclimab and IMVT-1402 targets the neonatal Fc receptor (FcRn).